The Nomura Small Cap Core Fund trailed its benchmark in Q2 2026 despite an exceptionally strong rally in small-cap stocks. Read the full analysis for more details.
Investor's Business Daily on MSN
Guardant Health dives after losing a patent dispute; judge orders royalties
Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...
Investor's Business Daily on MSN
IBD stock of the day, Travere Therapeutics, tests another breakout. Can the stock get any 'sweeter?'
Travere Therapeutics is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are clearing a fresh buy ...
Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. Click here to read ...
Everest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of ...
Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical ...
Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while ...
Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results